Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second-generation vaccines against leishmaniasis.

Rhea N Coler1, Steven G Reed

  • 1The Infectious Disease Research Institute, 1124 Columbia Street, Suite 600, Seattle, WA 98104, USA.

Trends in Parasitology
|April 20, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Schistosomiasis vaccine SchistoShield® induces functional immune memory responses in US and African populations.

NPJ vaccines·2026
Same author

Junction opener enables CAR T cell treatment of solid tumors.

Scientific reports·2026
Same author

Safety and immunogenicity of the Sm-p80 GLA-SE schistosomiasis vaccine.

NPJ vaccines·2025
Same author

Diagnostic potential of GLP recombinant antigens in whole blood assays for Leishmania infantum infection.

Parasites & vectors·2025
Same author

T cell-macrophage interactions in tuberculosis: What we've got here is failure to communicate.

Journal of internal medicine·2025
Same author

From Yesterday to Tomorrow: How Vaccine Platforms Have Shaped the Vaccine and Treatment Evaluation Units.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same journal

Hidden diversity in Trichuris control.

Trends in parasitology·2026
Same journal

The second Cryptosporidium meeting: Edinburgh's parasite deep dive.

Trends in parasitology·2026
Same journal

Evolution of generalism under Muller's ratchet.

Trends in parasitology·2026
Same journal

Next generation in parasitology 2026: Connecting young parasitologists across Europe.

Trends in parasitology·2026
Same journal

Disrupted barriers, evolved risks: toward precision One Health in arthropod allergy.

Trends in parasitology·2026
Same journal

Unveiling malaria history using ancient genomes.

Trends in parasitology·2026
See all related articles

Developing effective vaccines against leishmaniasis is crucial due to drug resistance. Second-generation vaccines show promise for treating and preventing multiple Leishmania species (diseases).

Area of Science:

  • Parasitology
  • Immunology
  • Vaccinology

Background:

  • Leishmania parasites cause diverse human diseases, including cutaneous, visceral, mucosal, and diffuse cutaneous leishmaniasis.
  • Chemotherapy for leishmaniasis faces challenges due to drug resistance and toxicity, highlighting the need for alternative interventions.
  • Understanding immunopathogenesis and protective immunity is key to designing effective vaccines.

Purpose of the Study:

  • To review advances in second-generation vaccine development for leishmaniasis.
  • To discuss the potential of a single vaccine to protect against multiple Leishmania species and disease forms.
  • To highlight the characteristics of an ideal vaccine for treating and preventing leishmaniasis.

Main Methods:

  • Review of scientific literature on leishmaniasis vaccine research.

Related Experiment Videos

  • Analysis of identified and characterized vaccine candidate antigens.
  • Focus on second-generation vaccine strategies and their progress.

    • Main Results:

    • Several potential vaccine candidate antigens have been identified and characterized.
    • Second-generation vaccines are being developed to overcome limitations of earlier approaches.
    • Leishmania vaccines offer a unique opportunity for broad-spectrum protection against multiple species and disease manifestations.

    Conclusions:

    • The development of effective and safe vaccines is a priority for combating leishmaniasis globally.
    • Second-generation vaccines represent a promising advancement in leishmaniasis prevention and treatment.
    • Further research into vaccine candidates and immunopathogenesis will be critical for successful vaccine implementation.